Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

C10AB05 FENOFIBRATUM CAPS. 100 mg

LIPANTHYL(R) 100 100 mg LAB. FOURNIER SA
C10AB05 FENOFIBRATUM CAPS. 160 mg

LIPOFIB 160 mg 160 mg TERAPIA S.A.

C10AB05 FENOFIBRATUM COMPR. FILM. ELIB. 160 mg

MODIF.

LIPANTHYL(R) SUPRA 160 mg 160 mg LAB. FOURNIER SA
C10AB05 FENOFIBRATUM CAPS. 200 mg

LIPOFIB 200 mg 200 mg TERAPIA S.A.

C10AB05 FENOFIBRATUM CAPS. PULB. MICRONIZATĂ 200 mg

FENOFIBRAT LPH 200 mg 200 mg LABORMED PHARMA SA

LIPANTHYL 200 M 200 mg LAB. FOURNIER SA

LIPIVIM 200 mg VIM SPECTRUM SRL

________________________________________________________________________________
______________________________________________________________________________

| 66 |D01AC02| MICONAZOLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

D01AC02 MICONAZOLUM CREMĂ 20 mg/g

MICONAL ECOBI 20 mg/g FARMACEUTICI ECOBI S.A.S.
D01AC02 MICONAZOLUM CREMĂ 2%

MEDACTER 2% FARAN LABORATORIES S.A.

MICONAZOL NITRAT 2% 2% SLAVIA PHARM SRL
D01AC02 MICONAZOLUM GEL 2%

DERMOZOL 2% PHARCOIMPEX 93 S.R.L.

________________________________________________________________________________
______________________________________________________________________________

| 67 |D01AC10| BIFONAZOLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

D01AC10 BIFONAZOLUM SOL. CUT. 0,01 g/ml

MYCOSPOR 0,01 g/ml BAYER HEALTHCARE AG
D01AC10 BIFONAZOLUM CREMĂ 100 g

MYCO-FLUSEMIDON 100 g ANFARM HELLAS S.A.

PHARMACEUTICALS
D01AC10 BIFONAZOLUM CREMĂ 10 mg/g

BIAZOL 10 mg/g 10 mg/g GEDEON RICHTER ROMANIA SA

D01AC10 BIFONAZOLUM CREMĂ 1%

MYCOSPOR 1% BAYER HEALTHCARE AG

________________________________________________________________________________
______________________________________________________________________________

| 68 |D06BB03| ACICLOVIRUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

D06BB03 ACICLOVIRUM CREMĂ 50 mg/g

ACICLOVIR HYPERION 50 mg/g HYPERION S.A.

ACIKLOVIR CREMĂ 50 mg/g A & G MED TRADING S.R.L.

D06BB03 ACICLOVIRUM CREMĂ 5%

ACICLOVIR 5% OZONE LABORATORIES LTD.

ACICLOVIR 5% 5% GEDEON RICHTER ROMANIA SA

CLOVIRAL(R) 5% 5% ANTIBIOTICE SA

ZOVIRAX 5% THE WELLCOME FOUNDATION

LTD.

________________________________________________________________________________
______________________________________________________________________________

| 69 |D07AA02| HYDROCORTISONUM | Protocol: D001L |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

D07AA02 HYDROCORTISONUM UNGUENT 1,00%

HIDROCORTIZON 1% 1% ANTIBIOTICE SA

________________________________________________________________________________

______________________________________________________________________________

| 70 |D07AC01| BETAMETHASONUM | Protocol: D001L |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

D07AC01 BETAMETHASONUM CREMĂ 0,5 mg/g

BELODERM CREMĂ 0,5 mg/g A & G MED TRADING S.R.L.
D07AC01 BETAMETHASONUM UNGUENT 0,5 mg/g

BELODERM UNGUENT 0,5 mg/g A & G MED TRADING S.R.L.

D07AC01 BETAMETHASONUM CREMĂ 0.1%

BETADERM 0.1% E.I.P.I.CO. MED S.R.L.

D07AC01 BETAMETHASONUM UNGUENT 0.1%

BETADERM 0.1% E.I.P.I.CO. MED S.R.L.

________________________________________________________________________________
______________________________________________________________________________

| 71 |G01AF04| MICONAZOLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

G01AF04 MICONAZOLUM CAPS. MOI VAG. 1.2 g

MICONAL ECOBI 1.2 g FARMACEUTICI ECOBI S.A.S
G01AF04 MICONAZOLUM CREMĂ VAG. 20 mg/g

MICONALECOBI 20 mg/g FARMACEUTICI ECOBI S.A.S

G01AF04 MICONAZOLUM SOL. VAGINALĂ 2 mg/ml

MICONAL ECOBI 2 mg/ml FARMACEUTICI ECOBI S.A.S

G01AF04 MICONAZOLUM OVULE 50 mg

MICONALECOBI 50 mg FARMACEUTICI ECOBI S.A.S

G01AF04 MICONAZOLUM CREMĂ VAG. 2%

MEDACTER 2% FARAN LABORATORIES S.A.

MYCOHEAL 2% DAR AL DAWA PHARMA S.R.L.

________________________________________________________________________________

______________________________________________________________________________

| 72 |G02AB03| ERGOMETRINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

G02AB03 ERGOMETRINUM SOL. INJ. 0.2 mg/ml

MALEAT DE ERGOMETRINA 0.2 mg/ml ZENTIVA S.A.

0,2 mg/ml

________________________________________________________________________________
______________________________________________________________________________

| 73 |G03BA03| TESTOSTERONUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

G03BA03 TESTOSTERONUM SOL. INJ. 1000 mg/4 ml

NEBIDO 1000 mg/4 ml 1000 mg/4 ml SCHERING AG
G03BA03 TESTOSTERONUM CAPS. MOI 40 mg

UNDESTO(R) TESTOCAPS(R) 40 mg ORGANON NV

Prescriere limitată: Deficit androgenic la bărbaţi de cauză primară testiculară sau secundară hipotalamo-hipofizară (confirmat prin nivel plasmatic al testosteronului la cel puţin 2 determinări în două dimineţi diferite mai mic sau egal cu limita inferioară a valorilor reactivului utilizat).

Prescriere limitată: Micropenis, inducerea pubertăţii sau întârzierea constituţională a creşterii sau a pubertăţii la băieţi sub 18 ani.

G03BA03 TESTOSTERONUM GEL 50 mg

ANDROGEL 50 mg 50 mg LAB. BESINS INTERNATIONAL

________________________________________________________________________________
______________________________________________________________________________

| 74 |G03CA03| ESTRADIOLUM* | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Utilizat în simptomele caracteristice post-menopauzei, în cazul în care terapia estrogenică în doze reduse a demonstrat intoleranţa la administrarea orală cu estrogeni.